ArticleScientific reports2025
Retrospective exploratory dual-center analysis of temporary transvenous cardiac pacing in cardiogenic shock.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Temporary transvenous cardiac pacing (TTP) is commonly used to manage hemodynamically compromising, drug-refractory brady- and tachyarrhythmias in the intensive care setting. Despite previous studies analyzing TTP treatment, data on its use in patients with cardiogenic shock (CS) remain limited. This retrospective exploratory analysis aimed to investigate the utilization of TTP in patients experiencing CS, with a particular focus on treatment characteristics, complication rates, predictive factors, and outcomes across different subgroups. We retrospectively included registry data from 184 patients who underwent TTP therapy from 1561 cases of CS treated at the Intensive Care Units (ICUs) of two university hospitals in Germany between 2010 and 2023. Bradycardia due to acute myocardial infarction was the primary indication for TTP implantation in patients with CS. The median duration of TTP therapy was 65 h, during which complications occurred in 12.0% of cases, 3.3% were classified as severe. We found that culprit lesions in the Right Coronary Artery (RCA) were more likely to necessitate TTP treatment in patients with acute myocardial infarction complicated by cardiogenic shock (AMI-CS) (OR 2.52, 95% CI 1.54-4.11, p < 0.001). In non-AMI-CS patients, age (OR 1.03, 95% CI 1.01-1.05, p < 0.005) and myocarditis (OR 3.21, 95% CI 1.19-8.64, p = 0.02) were associated with a higher incidence of TTP therapy during ICU treatment. Further studies are needed to validate these observations.Trial registration: LMUshock registry (WHO International Clinical Trials Registry Platform Number DRKS00015860).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.